EA032054B1 - Моноклональное антитело или его антигенсвязывающий фрагмент, его применения, клеточная линия гибридомы для его получения, фармацевтическая композиция, содержащая моноклональное антитело или его антигенсвязывающий фрагмент, способ диагностики in vitro амилоид-ассоциированного заболевания и набор для его осуществления - Google Patents

Моноклональное антитело или его антигенсвязывающий фрагмент, его применения, клеточная линия гибридомы для его получения, фармацевтическая композиция, содержащая моноклональное антитело или его антигенсвязывающий фрагмент, способ диагностики in vitro амилоид-ассоциированного заболевания и набор для его осуществления Download PDF

Info

Publication number
EA032054B1
EA032054B1 EA201301029A EA201301029A EA032054B1 EA 032054 B1 EA032054 B1 EA 032054B1 EA 201301029 A EA201301029 A EA 201301029A EA 201301029 A EA201301029 A EA 201301029A EA 032054 B1 EA032054 B1 EA 032054B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
amyloid
disease
antibodies
antigen
Prior art date
Application number
EA201301029A
Other languages
English (en)
Russian (ru)
Other versions
EA201301029A1 (ru
Inventor
Мартин Клайншмидт
Штефан Шиллинг
Йенс-Ульрих Рафельд
Ханс-Ульрих Демут
Кристин Эберманн
Original Assignee
Пробиодруг Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пробиодруг Аг filed Critical Пробиодруг Аг
Publication of EA201301029A1 publication Critical patent/EA201301029A1/ru
Publication of EA032054B1 publication Critical patent/EA032054B1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
EA201301029A 2011-03-16 2012-03-16 Моноклональное антитело или его антигенсвязывающий фрагмент, его применения, клеточная линия гибридомы для его получения, фармацевтическая композиция, содержащая моноклональное антитело или его антигенсвязывающий фрагмент, способ диагностики in vitro амилоид-ассоциированного заболевания и набор для его осуществления EA032054B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161453449P 2011-03-16 2011-03-16
PCT/EP2012/054629 WO2012123562A1 (en) 2011-03-16 2012-03-16 Diagnostic antibody assay

Publications (2)

Publication Number Publication Date
EA201301029A1 EA201301029A1 (ru) 2014-05-30
EA032054B1 true EA032054B1 (ru) 2019-04-30

Family

ID=45833428

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201301029A EA032054B1 (ru) 2011-03-16 2012-03-16 Моноклональное антитело или его антигенсвязывающий фрагмент, его применения, клеточная линия гибридомы для его получения, фармацевтическая композиция, содержащая моноклональное антитело или его антигенсвязывающий фрагмент, способ диагностики in vitro амилоид-ассоциированного заболевания и набор для его осуществления

Country Status (15)

Country Link
US (2) US8809508B2 (enExample)
EP (1) EP2686346B1 (enExample)
JP (1) JP6220675B2 (enExample)
KR (1) KR102020072B1 (enExample)
CN (1) CN103459421B (enExample)
AU (1) AU2012228236B2 (enExample)
BR (1) BR112013023211B1 (enExample)
CA (1) CA2828433C (enExample)
DK (1) DK2686346T3 (enExample)
EA (1) EA032054B1 (enExample)
IL (1) IL227847A0 (enExample)
MX (1) MX343873B (enExample)
SG (1) SG192805A1 (enExample)
WO (1) WO2012123562A1 (enExample)
ZA (1) ZA201305946B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6454651B2 (ja) 2013-03-15 2019-01-23 プロビオドルグ エージー 新規阻害剤
US20170363645A1 (en) 2014-12-19 2017-12-21 Probiodrug Ag Novel Method for the Detection of pGlu-Abeta Peptides
EP3262070A4 (en) * 2015-02-24 2018-07-25 Rpeptide, LLC Anti-amyloid-beta antibodies
CA2992386A1 (en) * 2015-07-16 2017-01-19 Probiodrug Ag Humanized antibodies
GB201910697D0 (en) * 2019-07-26 2019-09-11 Binding Site Group Ltd Lonisation control
KR20220066161A (ko) * 2019-10-01 2022-05-23 리플리겐 코포레이션 유체의 단백질 농도 측정
KR102790945B1 (ko) * 2022-09-23 2025-04-04 경성대학교 산학협력단 베타-아밀로이드 42를 이용한 치매 진단 방법 및 이를 이용한 치매 진단 키트
CN121253823A (zh) * 2025-10-10 2026-01-02 山东九嘉生物科技有限公司 一种用于检测胃蛋白酶原ⅰ的化学发光试剂盒及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009149485A2 (en) * 2008-06-12 2009-12-17 Affiris Ag Compounds for treating amyloidoses
US20100021478A1 (en) * 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
WO2010128139A1 (en) * 2009-05-08 2010-11-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
CN101935352A (zh) * 1999-12-08 2011-01-05 智力神经系统学公司 作为免疫原的嵌合肽及其抗体,以及利用嵌合肽或抗体进行免疫的方法
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
EP1523499A2 (en) 2002-07-24 2005-04-20 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
KR101099206B1 (ko) 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
ES2259270B1 (es) 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
EP2043687A4 (en) 2006-06-29 2010-03-17 Centocor Ortho Biotech Inc ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2091945B1 (en) 2006-11-09 2014-01-15 Probiodrug AG Novel inhibitors of glutaminyl cyclase
US7741354B2 (en) 2006-11-09 2010-06-22 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5523107B2 (ja) 2006-11-30 2014-06-18 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
US7803810B2 (en) 2007-03-09 2010-09-28 Probiodrug Ag Inhibitors
DK2160389T3 (da) 2007-04-18 2014-06-23 Probiodrug Ag Thioxoquinazolinonderivater som glutaminylcyclaseinhibitorer
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
US8227498B2 (en) 2007-04-18 2012-07-24 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2008128986A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Urea derivatives as glutaminyl cyclase inhibitors
WO2008128981A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors
WO2008128984A1 (en) 2007-04-20 2008-10-30 Probiodrug Ag Aminopyrimidine derivatives as glutaminyl cyclase inhibitors
JP2011500059A (ja) * 2007-10-15 2011-01-06 セントコア・オーソ・バイオテツク・インコーポレーテツド ヒト抗アミロイド抗体、組成物、方法及び使用
US20120100129A1 (en) * 2009-06-29 2012-04-26 Gellerfors Paer N-Terminal Truncated Protofibrils/Oligomers for Use in Therapeutic and Diagnostic Methods for Alzheimer's Disease and Related Disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009149485A2 (en) * 2008-06-12 2009-12-17 Affiris Ag Compounds for treating amyloidoses
US20100021478A1 (en) * 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
WO2010128139A1 (en) * 2009-05-08 2010-11-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DIETMAR RUDOLF THAL ; ESTIBALIZ CAPETILLO-ZARATE ; CHRISTIAN SCHULTZ ; UDO R�B ; TAKAOMI C. SAIDO ; HARUYASU YAMAGUCHI ; CHRISTIAN: "Apolipoprotein E co-localizes with newly formed amyloid β-protein (Aβ) deposits lacking immunoreactivity against N-terminal epitopes of Aβ in a genotype-dependent manner", ACTA NEUROPATHOLOGICA ;, SPRINGER, BERLIN, DE, vol. 110, no. 5, 1 November 2005 (2005-11-01), Berlin, DE, pages 459 - 471, XP019340810, ISSN: 1432-0533, DOI: 10.1007/s00401-005-1053-1 *
IWATSUBO T, ET AL.: "FULL-LENGTH AMYLOID-BETA(1-42(43)) AND AMINO-TERMINALLY MODIFIED AND TRUNCATED AMYLOID-BETA42(43) DEPOSIT IN DIFFUSE PLAQUES", AMERICAN JOURNAL OF PATHOLOGY., ELSEVIER INC., US, vol. 149, no. 06, 1 December 1996 (1996-12-01), US, pages 1823 - 1830, XP009008612, ISSN: 0002-9440 *
KANGNING LIU ; INGRID SOLANO ; DAVID MANN ; CYNTHIA LEMERE ; MARC MERCKEN ; JOHN Q. TROJANOWSKI ; VIRGINIA M.-Y. LEE: "Characterization of Aβ11-40/42 peptide deposition in Alzheimer’s disease and young Down’s syndrome brains: implication of N-terminally truncated Aβ species in the pathogenesis of Alzheimer’s disease", ACTA NEUROPATHOLOGICA ;, SPRINGER, BERLIN, DE, vol. 112, no. 2, 1 June 2006 (2006-06-01), Berlin, DE, pages 163 - 174, XP019426174, ISSN: 1432-0533, DOI: 10.1007/s00401-006-0077-5 *
SAITO TAKANOMI C ET AL: "Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain.", NEUROSCIENCE LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 215, no. 3, 1 January 1996 (1996-01-01), AMSTERDAM, NL, pages 173 - 176, XP002236342, ISSN: 0304-3940, DOI: 10.1016/0304-3940(96)12970-0 *

Also Published As

Publication number Publication date
KR102020072B1 (ko) 2019-11-04
JP2014509860A (ja) 2014-04-24
US9657089B2 (en) 2017-05-23
EA201301029A1 (ru) 2014-05-30
CN103459421B (zh) 2017-07-14
CN103459421A (zh) 2013-12-18
EP2686346A1 (en) 2014-01-22
BR112013023211B1 (pt) 2022-11-08
AU2012228236A1 (en) 2013-10-03
WO2012123562A1 (en) 2012-09-20
ZA201305946B (en) 2014-10-29
US20120237529A1 (en) 2012-09-20
AU2012228236B2 (en) 2016-10-27
EP2686346B1 (en) 2016-12-14
CA2828433A1 (en) 2012-09-20
US8809508B2 (en) 2014-08-19
IL227847A0 (en) 2013-09-30
MX2013010571A (es) 2013-12-02
NZ614217A (en) 2015-12-24
CA2828433C (en) 2020-08-04
JP6220675B2 (ja) 2017-11-01
MX343873B (es) 2016-11-25
KR20140006019A (ko) 2014-01-15
DK2686346T3 (en) 2017-03-27
BR112013023211A2 (pt) 2016-11-22
US20140255414A1 (en) 2014-09-11
SG192805A1 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
CN102131519B (zh) 诊断抗体测定
US9657089B2 (en) Diagnostic antibody assay
US11629183B2 (en) Monoclonal antibodies targeting microtubule-binding domain of tau protein and methods of detecting tau protein in vivo
HK1192568B (en) Diagnostic antibody assay
HK1192568A (en) Diagnostic antibody assay
NZ614217B2 (en) Diagnostic antibody assay
HK1158946B (en) Diagnostic antibody assay

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG TM

TC4A Change in name of a patent proprietor in a eurasian patent
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title